Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Queensland Health
Teva
US Department of Justice
Fuji
Cipla
McKinsey
Julphar
US Army
Farmers Insurance

Generated: January 21, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 019832

« Back to Dashboard

NDA 019832 describes SULFAMYLON, which is a drug marketed by Mylan Institutional and is included in two NDAs. It is available from one supplier. Additional details are available on the SULFAMYLON profile page.

The generic ingredient in SULFAMYLON is mafenide acetate. There are four drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the mafenide acetate profile page.
Summary for 019832
Tradename:SULFAMYLON
Applicant:Mylan Institutional
Ingredient:mafenide acetate
Patents:0
Therapeutic Class:Antibacterials
Formulation / Manufacturing:see details
Pharmacology for NDA: 019832
Ingredient-typeMethylated Sulfonamides
Medical Subject Heading (MeSH) Categories for 019832
Suppliers and Packaging for NDA: 019832
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
SULFAMYLON mafenide acetate FOR SOLUTION;TOPICAL 019832 NDA Mylan Institutional Inc. 51079-624 51079-624-85 5 PACKET in 1 CARTON (51079-624-85) > 1 POWDER, FOR SOLUTION in 1 PACKET (51079-624-84)

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:FOR SOLUTION;TOPICALStrength5%
Approval Date:Jun 5, 1998TE:ATRLD:Yes

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
UBS
Julphar
Queensland Health
McKinsey
QuintilesIMS
Harvard Business School
Moodys
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot